Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 2, 2026
Daily News
April 2, 2026
- JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
April 2, 2026
- Five Groups Urge Action to Secure Medical Supplies amid Iran War
April 2, 2026
- Gilead Names Andrew Hexter as Japan President
April 2, 2026
- JPMA Unveils Committee Action Plans, Prioritizes Innovation-Focused Drug Pricing
April 2, 2026
- Santen Sets May Launch Date for Upneeq as Non-Reimbursed Drug
April 2, 2026
- Shionogi Completes ViiV Stake Increase to 21.7%
April 2, 2026
- UCB’s Kikuchi Appointed EFPIA Japan Vice Chair
April 2, 2026
- Kei Kaneda Becomes President of Moderna Japan
April 2, 2026
- Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
- Teijin Slashes FY2025 Forecast on Pharma Impairment
April 2, 2026
- MHLW Revises Biological Raw Material Rules, Clarifies Donor Testing Flexibility
April 2, 2026
- BIKEN to Take Full Control of Vaccine JV with Tanabe Pharma
April 2, 2026
- Nippon Kayaku to Buy Fuji Yakuhin’s Injectable Plant in Japan
April 2, 2026
- Yoshindo Eyes Biosimilar API Production from 2028 with Cytiva Support
April 2, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…